Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database

BACKGROUND: Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19) affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study revi...

全面介紹

Na minha lista:
書目詳細資料
發表在:Expert Opin Drug Saf
Main Authors: Charan, Jaykaran, Dutta, Siddhartha, Kaur, Rimplejeet, Bhardwaj, Pankaj, Sharma, Praveen, Ambwani, Sneha, Jahan, Iffat, Abubakar, Abdullahi Rabiu, Islam, Salequl, Hardcastle, Timothy Craig, Rahman, Nor Azlina A, Lugova, Halyna, Haque, Mainul
格式: Artigo
語言:Inglês
出版: Taylor & Francis 2021
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290369/
https://ncbi.nlm.nih.gov/pubmed/34162299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2021.1946513
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍